Petros Pharmaceuticals, Inc.
PTPI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.16 | -0.35 | 1.23 |
| FCF Yield | -3.32% | -16.83% | -10.61% | -1.31% |
| EV / EBITDA | -7.65 | -9.56 | -8.82 | -539.80 |
| Quality | ||||
| ROIC | 21,749.66% | -56.02% | -59.60% | -49.57% |
| Gross Margin | 76.28% | 71.98% | 61.79% | 79.52% |
| Cash Conversion Ratio | 0.18 | 0.93 | 0.64 | 1.32 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.16% | -9.33% | -14.42% | -20.55% |
| Free Cash Flow Growth | 65.55% | 40.41% | -7.88% | 22.52% |
| Safety | ||||
| Net Debt / EBITDA | -0.34 | 1.20 | -0.03 | 14.33 |
| Interest Coverage | -31.52 | -25.40 | -26.59 | -48.96 |
| Efficiency | ||||
| Inventory Turnover | 0.90 | 1.01 | 1.26 | 3.08 |
| Cash Conversion Cycle | -265.00 | 116.54 | 129.93 | -778.30 |